BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases
The new cohort will include patients living with IRDs caused by mutations in multiple genes.
- The new cohort will include patients living with IRDs caused by mutations in multiple genes.
- “BlueRock is developing a pipeline of cell therapies that we believe has great potential for restoring vision in people living with blindness caused by retinal disease,” said Ahmed Enayetallah, Senior Vice President and Head of Development for BlueRock Therapeutics.
- Primary photoreceptor diseases are a subgroup of inherited retinal diseases that includes retinitis pigmentosa and cone- rod dystrophies.
- OpCT-001 aims to restore vision loss caused by these diseases by replacing degenerated tissue in the retina with functional cells.